Pharmala Biotech Holdings Inc.
MDXXF
$0.07
$0.000.00%
OTC PK
| 11/30/2025 | 08/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -24.11% | 102.81% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -24.11% | 102.81% | |||
| Cost of Revenue | 0.81% | 264.71% | |||
| Gross Profit | -27.75% | 90.48% | |||
| SG&A Expenses | -12.36% | -3.37% | |||
| Depreciation & Amortization | 0.00% | 2.90% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.81% | -3.45% | |||
| Operating Income | -0.30% | 32.83% | |||
| Income Before Tax | -11.47% | 29.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -11.47% | 29.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -11.47% | 29.39% | |||
| EBIT | -0.30% | 32.83% | |||
| EBITDA | -0.22% | 33.83% | |||
| EPS Basic | 0.00% | 22.86% | |||
| Normalized Basic EPS | 17.65% | 22.73% | |||
| EPS Diluted | 0.00% | 22.86% | |||
| Normalized Diluted EPS | 17.65% | 22.73% | |||
| Average Basic Shares Outstanding | 9.04% | -5.92% | |||
| Average Diluted Shares Outstanding | 9.04% | -5.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||